Literature DB >> 28092495

Nonhypervascular Pancreatic Neuroendocrine Tumors: Differential Diagnosis from Pancreatic Ductal Adenocarcinomas at MR Imaging-Retrospective Cross-sectional Study.

Sun Kyung Jeon1, Jeong Min Lee1, Ijin Joo1, Eun Sun Lee1, Hyun Jeong Park1, Jin-Young Jang1, Ji Kon Ryu1, Kyung Bun Lee1, Joon Koo Han1.   

Abstract

Purpose To determine useful magnetic resonance (MR) imaging features to differentiate nonhypervascular pancreatic neuroendocrine tumors (PNETs) from pancreatic ductal adenocarcinomas (PDACs). Materials and Methods The institutional review board approved this retrospective study and waived the informed consent requirement. Seventy-four patients with surgically confirmed PNETs and 82 patients with PDACs who underwent gadobutrol-enhanced MR imaging were included. Two radiologists independently evaluated the morphologic characteristics and temporal enhancement patterns of each tumor. Quantitative analysis, including measurement of tumor size, maximal upstream parenchymal thickness (MUPT), contrast-to-noise ratio, and apparent diffusion coefficient values, was performed. Uni- and multivariate logistic regression analyses were performed to identify relevant features to differentiate between PNETs and PDACs. Results On the basis of arterial enhancement, 38 PNETs (51%, 38 of 74) were hypervascular and 36 PNETs (49%, 36 of 74) were nonhypervascular. At MR imaging, nonhypervascular PNETs showed significantly higher frequencies of a well-defined margin, portal hyper- or isoenhancement, and MUPT of 10 mm or greater but lower frequencies of ductal dilatation, vascular invasion, and peripancreatic infiltration when compared with PDACs (P < .05 for all). At multivariate analysis, a well-defined margin and portal hyper- or isoenhancement were independent significant differentiators of PNETs from PDACs (odds ratio, 20.3 and 16.1, respectively). When applying the criteria of a well-defined margin and portal hyper- or isoenhancement, 64% of sensitivity and 99% of specificity were observed for the differential diagnosis of PNETs from PDACs. Conclusion A well-defined margin and hyper- or isoenhancement in the portal venous phase are useful MR imaging features that are more common in nonhypervascular PNETs and may help discriminate nonhypervascular PNETs from PDACs. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28092495     DOI: 10.1148/radiol.2016160586

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  23 in total

1.  Deep learning for World Health Organization grades of pancreatic neuroendocrine tumors on contrast-enhanced magnetic resonance images: a preliminary study.

Authors:  Xuan Gao; Xiaolin Wang
Journal:  Int J Comput Assist Radiol Surg       Date:  2019-09-26       Impact factor: 2.924

Review 2.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 3.  Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon.

Authors:  Anna La Salvia; Irene Persano; Elena Parlagreco; Alessandro Audisio; Massimiliano Cani; Maria Pia Brizzi
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

4.  MRI Feature-Based Nomogram Model for Discrimination Between Non-Hypervascular Pancreatic Neuroendocrine Tumors and Pancreatic Ductal Adenocarcinomas.

Authors:  Jiake Xu; Jie Yang; Ye Feng; Jie Zhang; Yuqiao Zhang; Sha Chang; Jingqiang Jin; Xia Du
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

5.  Interesting pancreatic tumour in the background of Tuberous Sclerosis.

Authors:  Jmv Amarjothi; Jeyasudhahar Jesudason; Villalan Ramasamy; Ol Naganath Babu
Journal:  BMJ Case Rep       Date:  2019-08-04

6.  Quantitative 3D Assessment of 68Ga-DOTATOC PET/MRI with Diffusion-Weighted Imaging to Assess Imaging Markers for Gastroenteropancreatic Neuroendocrine Tumors: Preliminary Results.

Authors:  Lisa C Adams; Keno K Bressem; Julia Brangsch; Carolin Reimann; Kristin Nowak; Winfried Brenner; Marcus R Makowski
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 10.057

7.  Differentiation of atypical pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas: Using whole-tumor CT texture analysis as quantitative biomarkers.

Authors:  Jiali Li; Jingyu Lu; Ping Liang; Anqin Li; Yao Hu; Yaqi Shen; Daoyu Hu; Zhen Li
Journal:  Cancer Med       Date:  2018-08-27       Impact factor: 4.452

8.  Differentiation between non-hypervascular pancreatic neuroendocrine tumour and pancreatic ductal adenocarcinoma on dynamic computed tomography and non-enhanced magnetic resonance imaging.

Authors:  Kazuyoshi Ohki; Takao Igarashi; Hirokazu Ashida; Megumi Shiraishi; Yosuke Nozawa; Hiroya Ojiri
Journal:  Pol J Radiol       Date:  2019-03-13

9.  The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis.

Authors:  Chuangen Guo; Xiaoling Zhuge; Qidong Wang; Wenbo Xiao; Zhonglan Wang; Zhongqiu Wang; Zhan Feng; Xiao Chen
Journal:  Cancer Imaging       Date:  2018-10-17       Impact factor: 3.909

Review 10.  Imaging presentation of pancreatic neuroendocrine neoplasms.

Authors:  Valentina Ciaravino; Riccardo De Robertis; Paolo Tinazzi Martini; Nicolò Cardobi; Sara Cingarlini; Antonio Amodio; Luca Landoni; Paola Capelli; Mirko D'Onofrio
Journal:  Insights Imaging       Date:  2018-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.